1,650 Companies Later, What’s Next for Catalonia’s Life Sciences Sector?

Market Insights

image description

Twenty years after Biocat’s creation, Catalonia has the research, investment and companies. The question now is whether it can scale innovation, develop the right talent and compete internationally.

Twenty years ago, Catalonia’s life sciences sector counted 856 companies. Today, that figure stands at 1,650. Over the same period, the sector’s contribution to Catalonia’s GDP has risen from 6.8% to 7.6%, while startups and scaleups have attracted more than €2.7 billion in cumulative investment.

The figures, presented at Biocat’s 20th anniversary, tell the story of an ecosystem that has grown considerably in size and economic significance. But the discussions among investors, hospital directors, pharmaceutical executives and biotech founders pointed to a different concern: what comes after that growth?

Catalonia has built a substantial scientific and entrepreneurial base. Turning it into companies that can develop treatments, manufacture technologies and compete internationally presents a different set of challenges.

Those challenges were evident throughout the anniversary discussions, from the need for specialised investment and industrial infrastructure to the difficulties of bringing innovation into healthcare systems. One issue repeatedly crossed the conversation: whether organisations have the leadership, expertise and structures required to take the next step.

Biocat’s creation helped bring together organisations that had previously worked largely within their own scientific, clinical or business environments. The ambition was not simply to increase research activity, but to build a network capable of connecting that research with entrepreneurs, investors and international markets.

Ignasi Biosca, CEO of Reig Jofre, recalled that the process was far from straightforward. CatalunyaBio, now part of Catalonia.health, faced difficult periods in its early years, including a moment when its continuity was in question. According to Biosca, the commitment of individuals from both the public and private sectors helped sustain the initiative.

“I say public and private, not public or private.”

Ignasi Biosca, CEO of Reig Jofre — translated from Catalan

It was a distinction Biosca made deliberately. The development of the BioRegion required cooperation between institutions and businesses rather than treating their interests as competing alternatives.

Montserrat Vendrell, former Director General of Biocat and Partner at Asabys, pointed to two milestones in building that shared identity: the first BioRegion Forum in 2008, which brought together more than 1,000 participants according to her account, and the 2012 delegation to Boston, involving over 70 companies.

These initiatives helped give the sector a stronger international presence and a sense of belonging to a wider community.

For a research team developing a new therapy, securing scientific results is only one stage of a much longer process. Taking that discovery towards patients requires funding, clinical development, regulatory expertise and an organisation capable of managing all three.

For Joël Jean-Mairet, co-founder of Ysios Capital, this was one of the gaps that specialised investors helped address. Catalonia already had strong research institutions and hospitals, but emerging companies also needed business experience, international investor networks and access to multidisciplinary teams.

Funding was part of the solution; building organisations capable of putting that funding to work was equally important.

A biotech company’s organisational needs change considerably as it moves from scientific discovery towards clinical development, industrialisation and commercialisation. A business initially structured around researchers and founders may later need experienced executives, regulatory specialists, clinical development leaders, financial management and international business development capabilities.

For founders and investors, the difficulty is identifying when those capabilities become necessary. Hiring too late can slow a critical development programme. Building a large organisation too early, on the other hand, can place unnecessary pressure on a company’s financial resources.

The appropriate structure depends on the technology, available funding and milestones the company is trying to achieve.

Developing a promising technology is one challenge. Producing it reliably, at scale and under the regulatory requirements of the healthcare industry is another.

HIPRA offers an example of what an integrated model can look like. During the anniversary discussions, Carles Fàbrega, General Manager of Human Health, described how the company operates across research, development, industrial scale-up and manufacturing.

That structure also shapes how HIPRA competes for talent. Based outside Barcelona’s main metropolitan area, the company must give specialised professionals compelling reasons to consider a career in Girona. For Fàbrega, the opportunity to participate in a long-term industrial project is central to that proposition.

INBRAIN Neuroelectronics illustrates a different route towards industrial scale. Its founder and CEO, Carolina Aguilar, described a company developing brain-computer interfaces while building international partnerships and semiconductor manufacturing capabilities. Aguilar said INBRAIN had attracted 130 professionals from 30 countries. She also discussed the company’s work on three products and its collaborations with Mayo Clinic and Microsoft.

One remark captured the technological ambition behind those partnerships:

“For us, data is therapy.”

Carolina Aguilar, founder and CEO of INBRAIN Neuroelectronics — translated from Spanish

Aguilar was referring to INBRAIN’s work on using data from neural interfaces to inform therapeutic interventions in real time.

Her argument went beyond technological development. The company must achieve sufficient scale for its innovations to reach patients beyond Catalonia, which requires expertise extending well beyond the original research team. For businesses working at the intersection of neuroscience, electronics and medical technology, finding those capabilities means competing for professionals across several highly specialised industries.

Carolina Aguilar, CEO of INBRAIN Neuroelectronics, speaking during a roundtable at Biocat's 20th anniversary event in Barcelona.
Carolina Aguilar, founder and CEO of INBRAIN Neuroelectronics, speaking during Biocat’s 20th anniversary roundtable on innovation, business growth and talent.

Healthcare innovation faces a problem that cannot always be solved by developing better technology. Hospitals may have professionals ready to adopt new solutions while the organisations around them struggle to change how care is delivered.

Manel del Castillo, President of CAIROS, pointed to this distinction during the second roundtable. Technologies such as remote monitoring or advanced therapies can progress faster than the organisational arrangements needed to implement them. His priorities were clear: greater organisational flexibility, protected time for professionals involved in innovation and incentives that reduce the personal risks associated with developing new approaches.

The implications extend beyond hospitals. A company can recruit experienced scientists and engineers, yet still struggle to innovate if decision-making is slow, responsibilities are unclear or specialist teams cannot work effectively together.

Hiring decisions and organisational design therefore need to be considered together. Adding expertise does not automatically solve the problems that prevent an organisation from using it.

As advanced therapies and new biomedical technologies move closer to clinical application, research infrastructure is becoming an increasingly important part of the debate.

Lluís Pareras, founder of Invivo Capital, argued that Catalonia needs to expand its capacity to deliver advanced therapies to patients. He used the analogy of widening a motorway: as new treatments become more widely available, existing infrastructure may struggle to accommodate demand.

The new Campus Clínic Barcelona represents one response to the need for closer integration between healthcare, research and innovation. Josep M. Campistol, Director General of Hospital Clínic de Barcelona, described its potential to bring together clinical care, teaching, scientific research and collaboration with companies.

Other initiatives are addressing different parts of the research system. Àngel Font, Executive Director of CaixaResearch Institute, discussed how philanthropic investment can complement public and private resources and support research that might otherwise struggle to secure early-stage funding.

Laia de Nadal, Rector of Pompeu Fabra University, highlighted the Ciutadella del Coneixement as an opportunity to strengthen research collaboration, knowledge transfer and the attraction of scientific talent. She also stressed the importance of diversified funding and more flexible structures.

These projects address different needs, but they share a practical objective: reducing the distance between scientific discoveries and their eventual application in healthcare.

For biotech companies, the talent challenge changes with each stage of development.

An early-stage spin-off may rely heavily on its scientific founders and a small research team. As it moves towards clinical development, the organisation needs people who understand regulatory pathways, trial management and the operational demands of bringing a product closer to patients.

Industrial scale-up introduces another set of requirements, including manufacturing, quality assurance, process engineering and supply chain management. Companies entering international markets must then strengthen their commercial, financial and leadership capabilities.

These transitions are not always straightforward: A successful researcher may not have experience managing a growing organisation. Equally, an executive recruited from a large pharmaceutical company may need to adapt to the uncertainty and resource constraints of a smaller biotech.

For founders and investors, the challenge is to identify which capabilities are missing before they become obstacles to the company’s next milestone. That requires a more considered approach to hiring than simply replicating the structure of larger competitors. The right appointment depends on the technology, development stage, funding position and responsibilities already covered by the existing team.

The debate around talent is therefore not limited to shortages of specialised professionals. It also concerns how companies define roles, distribute responsibilities and build leadership teams capable of managing increasingly complex operations.

Catalonia’s life sciences sector no longer needs to prove that it can produce excellent research or attract international investors. Twenty years of growth have established those capabilities.

The more difficult questions concern execution: Can promising technologies reach patients faster? Can emerging companies develop the industrial and commercial structures required to compete internationally? And can organisations attract the specialists and leaders they need without losing the agility that helped them grow?

The discussions at Biocat’s anniversary suggest that progress will depend as much on how organisations operate as on what their laboratories discover. For companies now moving from research into clinical development, manufacturing and international markets, those questions are becoming increasingly immediate.

The decisions they make about investment, leadership and talent will help determine what Catalonia’s next twenty years look like.


IKIGAI Talent Group specialises in recruitment and executive search across Life Sciences, Technology and other knowledge-intensive industries. We analyse how changing markets and business models influence the demand for specialised talent and leadership.

Sources and editorial notes: This article draws on the presentations and three roundtable discussions held during Biocat’s 20th anniversary event. Economic figures are based on Biocat’s official anniversary data. Quotations from Ignasi Biosca and Carolina Aguilar have been translated into English from their original remarks in Catalan and Spanish. Figures and company information attributed to individual speakers reflect their statements during the event.

Join the IKIGAI community!

Subscribe to our newsletter and stay up to date with the latest Market Insights, Talent Growth articles, salary benchmarks and opportunities across Technology, Digital and IT Sales.

Write to us!

If you’d like to know more about IKIGAI Talent, have any questions, or would like to collaborate with us, you can send an email to:

hello@ikigaitalentgroup.com

You can also book an online appointment through our calendar:

Come and see us!

If you’re more into coffee and conversation at the same table, we’ll be waiting for you at our offices:

Av. Diagonal 612, 7º 13ª, 08021 Barcelona

Follow us on:

Iniciar chat